Trials / Completed
CompletedNCT04049825
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Trial to Evaluate the Safety of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPB-111077 | OPB-111077+bendamustine |
| DRUG | OPB-111077 | OPB-111077+rituximab+bendamustine |
Timeline
- Start date
- 2019-11-22
- Primary completion
- 2025-03-25
- Completion
- 2026-01-19
- First posted
- 2019-08-08
- Last updated
- 2026-04-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04049825. Inclusion in this directory is not an endorsement.